Cancer therapy with vaccination using HLA-A24-restricted peptide from human vascular endothelial growth factor receptor 2: a phase I study in patients with unresectable colorectal cancer

Cancer therapy with vaccination using HLA-A24-restricted peptide from human vascular endothelial growth factor receptor 2: a phase I study in patients with unresectable colorectal cancer - KDR peptide vaccination:a phase I study in patients with unresectable colorectal cancer(A24)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000704

Enrollment

Registered

2007-05-02

Start date

2006-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

unresectable colorectal cancer

Interventions

Vaccination

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Performance status 0-2 HLA-A24 No response to CPT-11,5-FU, LV, Oxaliplatin etc,

Exclusion criteria

Exclusion criteria: pregnancy uncontroled infection uncontroled cerebral metastasis etc,

Design outcomes

Primary

Measure	Time frame
Safety	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026